Alert | Coronavirus and heart health - information for all
Why Differentiate FH?
FH IS UNDERDIAGNOSED, UNDERTREATED AND LIFE-THREATENING
FH is Different – “You never find an individual with FH. You always find a family.”
– Katherine A. Wilemon
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH.
If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population.
However, with optimal treatment an affected individual’s lifetime risk of cardiovascular disease approaches the risk in the general population.
FH IS ONE OF THE MOST COMMON GENETIC METABOLIC DISORDERS
Anne Tybjærg-Hansen, MD, DMSc –
“Total frequency is underestimated.”FH has the prevalence of 1 in 250 individuals worldwide.FH is an autosomal dominant genetic condition caused by mutations in the low-density lipoprotein receptor (LDLR) gene, and less commonly, by mutations in the apolipoprotein B (apoB) or the proprotein convertase subtilisin/kexin (PCSK9) genes,all of which Inhibit LDL-C metabolism. LDL-C is elevated from birth on and often leads to premature coronary heart disease resulting in early myocardial infarctions (MIs), in some cases as early as childhood in individuals with HoFH and second to sixth decade of life in individuals with HeFH. Individuals with FH have a significantly higher risk of developing CHD than unaffected individuals due to the lifetime exposure to elevated LDL-C. ^^The burden of LDL-C is significantly lower in individuals with early high-dose statin initiation Recent data have confirmed earlier studies indication that FH accounts for roughly 13,000 MIs In the US per year. Initial insights from the FH Foundation’s CASCADE FH Registry™ suggest that over 25% of FH patients in the registry have heart disease by the time they are diagnosed and the age of diagnosis remains too late for most. In addition a majority of the patients in the registry require more than one medication to lower cholesterol.
1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European heart journal 2013.
2. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S1-8.3. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Bmj 2008;337:a24234. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh G. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015;36:560–565.5. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Int J Cardiol 2014;171:309–325.6. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-207. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-28. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303(6807):893-896.9. Marks D, Thorogood M, Neil HA et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-1410. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e24511. O’Brien EC, deGoma EM, Moriarty PM, Linton MF, Shapiro MD, Duell PB, Ballantyne CM, Neal WA, Ahmad ZS, Duffy D, Hudgins LC, Hemphill LC, Underberg JA, Watson KE, Gidding SS, Baum SJ, Wilemon KA, Pickhardt D, Kindt I, Rader DJ, Roe MT, & Knowles JW. Initial Results from the CASCADE-FH Registry: CAscade Screening for Awareness and Detection of Familial Hypercholesterolemia. Clinical Cardiology 2015.